ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $25.00 Price Target at Stifel Nicolaus

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target lifted by Stifel Nicolaus from $24.00 to $25.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a “hold” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price would suggest a potential downside of 0.36% from the company’s previous close.

Several other research analysts also recently issued reports on the stock. Bank of America upped their price target on shares of ACADIA Pharmaceuticals from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Citigroup raised their price objective on shares of ACADIA Pharmaceuticals from $32.00 to $35.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Canaccord Genuity Group boosted their target price on shares of ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. HC Wainwright lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, June 30th. Finally, Weiss Ratings cut shares of ACADIA Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 1st. Twelve investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $33.00.

ACADIA Pharmaceuticals Stock Performance

Shares of ACAD opened at $25.09 on Tuesday. The company has a market cap of $4.30 billion, a price-to-earnings ratio of 11.40, a PEG ratio of 18.44 and a beta of 0.80. The stock has a fifty day moving average price of $22.98 and a two-hundred day moving average price of $23.28. ACADIA Pharmaceuticals has a 52-week low of $19.69 and a 52-week high of $28.35.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.02). ACADIA Pharmaceuticals had a return on equity of 9.61% and a net margin of 34.30%.The business had revenue of $268.10 million for the quarter, compared to the consensus estimate of $280.25 million. During the same quarter in the previous year, the company posted $0.11 EPS. ACADIA Pharmaceuticals’s revenue for the quarter was up 9.7% on a year-over-year basis. As a group, research analysts predict that ACADIA Pharmaceuticals will post 0.37 EPS for the current fiscal year.

Insider Transactions at ACADIA Pharmaceuticals

In other news, insider James Kihara sold 5,401 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $21.18, for a total value of $114,393.18. Following the transaction, the insider owned 24,509 shares of the company’s stock, valued at approximately $519,100.62. This trade represents a 18.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Mark C. Schneyer sold 3,506 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $21.79, for a total transaction of $76,395.74. Following the sale, the executive vice president owned 66,145 shares of the company’s stock, valued at approximately $1,441,299.55. This represents a 5.03% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 10,239 shares of company stock valued at $219,813. Corporate insiders own 26.20% of the company’s stock.

Institutional Trading of ACADIA Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Farther Finance Advisors LLC grew its holdings in ACADIA Pharmaceuticals by 67.5% during the 4th quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 386 shares during the period. Meeder Asset Management Inc. acquired a new position in shares of ACADIA Pharmaceuticals in the 4th quarter valued at $26,000. Transamerica Financial Advisors LLC boosted its position in shares of ACADIA Pharmaceuticals by 304.5% in the 4th quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 1,005 shares during the last quarter. Federated Hermes Inc. boosted its position in shares of ACADIA Pharmaceuticals by 277.5% in the 4th quarter. Federated Hermes Inc. now owns 1,612 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 1,185 shares during the last quarter. Finally, Leonteq Securities AG acquired a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter worth $52,000. Institutional investors and hedge funds own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.